PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

niacin Side Effects

The reactions most often reported to the FDA for niacin (also sold as Niaspan, Slo-Niacin), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

11,382
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of niacin come from 11,382 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 11,382 reports to the FDA Adverse Event Reporting System (FAERS) for niacin (Niaspan): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

11,382

Reports Mentioning Death

745

6.5% of reports — not proof the medicine caused the death

Hospitalizations

3,202

28.1% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

FATIGUE
750
NAUSEA
671
DIARRHOEA
630
DIZZINESS
546
DYSPNOEA
530
DRUG HYPERSENSITIVITY
495
PAIN
489
HEADACHE
473
ASTHENIA
441
FALL
380
PAIN IN EXTREMITY
375
ARTHRALGIA
373
RASH
348
VOMITING
346
PRURITUS
341
WEIGHT DECREASED
337
MYALGIA
324
BACK PAIN
306

Who Reports Side Effects

Gender Distribution

Female 4,580 (43%)
Male 6,137 (57%)
Unknown 17

Age Distribution

0-17 43 (1%)
18-44 571 (8%)
45-64 2,698 (37%)
65-74 2,198 (30%)
75+ 1,711 (24%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 745 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 264
RENAL FAILURE 60
FALL 55
MYOCARDIAL INFARCTION 46
DYSPNOEA 44
PNEUMONIA 42
CARDIAC FAILURE CONGESTIVE 41
ASTHENIA 40
VOMITING 38
CARDIAC FAILURE 34
HYPOTENSION 34
NAUSEA 34
ATRIAL FIBRILLATION 32
PAIN 32
GASTROINTESTINAL HAEMORRHAGE 30
CARDIAC ARREST 29
INTERNAL HAEMORRHAGE 29
RESPIRATORY ARREST 29
RESPIRATORY FAILURE 28

Reactions in Hospitalization Reports

Top reactions in 3,202 reports where hospitalization was an outcome.

Reaction Reports
NAUSEA 222
MYOCARDIAL INFARCTION 215
DYSPNOEA 214
FALL 209
PNEUMONIA 209
DIARRHOEA 207
FATIGUE 202
DIZZINESS 184
ASTHENIA 180
PAIN 180
VOMITING 180
GASTROINTESTINAL HAEMORRHAGE 164
CEREBROVASCULAR ACCIDENT 153
CHEST PAIN 143
DEHYDRATION 134
ACUTE KIDNEY INJURY 133
ANAEMIA 130
CARDIAC FAILURE CONGESTIVE 127
RENAL FAILURE 126

Compare niacin vs alirocumab →

What the FAERS Data Reveals About niacin Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 11,382 voluntary reports linked to niacin and its brand equivalents (Niaspan, Slo-Niacin), spanning 2004 through 2025. Of those, 745 (6.5%) listed death as an outcome and 3,202 (28.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 43% were female and 57% male; age distribution skews toward 45-64, with 2,698 reports in that bracket. The single most reported reaction is fatigue with 750 submissions, followed by nausea and diarrhoea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.